Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 2007

View Archived Issues

Recent Bayer patents report novel therapeutic agents for urological disorders

New agents for treating neurological disorders disclosed in recent patent literature

New therapeutic strategies for cancer imparted in recent patents

BENCHMRK studies reveal activity of raltegravir in triple-class resistant HIV

Interleukin-12 gene therapy safe in phase I ovarian cancer study

Maraviroc effective in phase IIb/III studies in CCR5-tropic HIV-1

rAAV HIV vaccine safe, well tolerated in healthy subjects

Entecavir selects for HIV resistance mutations

Idenix develops potent and selective anti-HIV agents

Treatment complete in phase II osteoarthritis study of Indaflex

MIV-701 begins clinical studies for osteoporosis

Novartis Consumer Health to copromote Vusion ointment to U.S. pediatricians

Encouraging proof-of-concept results for PA-325

Enrollment complete in phase I/II study of ALKS-29 in alcohol dependence

Financing at TransOral to support Intermezzo NDA filing

Enrollment completed in phase II study of CTA-018 for psoriasis

Sinovac updates progress of pandemic influenza vaccine study

Sunesis studies SNS-032 for advanced B-cell malignancies in clinic

Phase II study of faropenem in acute otitis media meets primary objective

Panzem NCD studied with Sutent in metastatic renal cell carcinoma

Roche's HPV tests accepted for FDA review

Enrollment completed in phase IIb study of AeroLEF

Sankyo and Biota license Hovione's inhaler technology for influenza

Amarin acquires rights to nasal lorazepam for emergency epilepsy seizures

Target enrollment reached in phase III trials of Puricase

Flurizan shows benefit in mild Alzheimer's patients

Topline MERLIN TIMI-36 results for ranolazine

Moli-1901 improves lung function in cystic fibrosis study

Lipitor approved for five new indications in heart disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...